CCT a risk factor for glaucoma damage

Article

CCT a risk factor for glaucoma damage

Central corneal thickness (CCT) and corneal hysteresis could present a pressure-independent risk factor for glaucoma damage, according to a report in the May issue of the American Journal of Ophthalmology.

N.G. Congdon and colleagues from the John Hopkins University School of Medicine conducted an observational study of 230 patients undergoing measurements for hysteresis, on the Reichert Ocular Response Analyser, and CCT by ultrasonic pachymetry. Charts were reviewed to determine highest known intraocular pressure (IOP), target IOP, diagnosis, number of years with glaucoma, cup-to-disk ratio (CDR), mean defect, pattern standard deviation, glaucoma hemifield test and the presence or absence of visual field progression. Of the 230 patients (127 female, 103 male) 85% had a diagnosis of primary open-angle glaucoma (POAG) or suspected POAG.

The researchers found that lower corneal hysteresis values (p=0.03) were associated with visual field progression, but CCT was not. When axial length was included in the model, hysteresis was not a significant risk factor (p=0.09). Thinner CCT measurements were associated with a higher CDR but neither CCT nor hysteresis were linked with mean defect, pattern standard deviation or glaucoma hemifield test. Thinner CCT was associated with the state of glaucoma damage, as indicated by CDR, and axial length and corneal hysteresis were linked to progressive field worsening.

It was concluded that CCT and hysteresis may constitute a risk factor for glaucoma damage, related to the composition of the eye wall itself.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
© 2024 MJH Life Sciences

All rights reserved.